Electromed, Inc. (NYSE: ELMD)

Electromed, Inc. develops, manufactures, markets and sells innovative airway clearance therapy products, primarily the SmartVest System, to patients with compromised pulmonary function. The company focuses on high frequency chest wall oscillation technology to help patients clear lung secretions and improve respiratory health. Electromed operates mainly in the United States with a direct to patient model that bypasses traditional home medical equipment distributors. Founded in 1992 and headquartered in New Prague, Minnesota, the firm has built its reputation on providing clinically effective and user friendly devices. Its mission emphasizes making therapy effective, convenient, and comfortable so patients can breathe easier and live better.

The company generates revenue from the sale and support of its SmartVest System, which includes the SmartVest SQL and SmartVest Clearway models, as well as single patient use products for acute care settings. In fiscal 2025, United States revenue totaled $63.8 million, of which 94.5% came from homecare sales, 4.9% from hospital sales, and the remainder from international markets. Revenue is derived largely from third party payer reimbursement under HCPCS code E0483, with patients often financing the device over one to 15 months through Medicare, Medicaid, and private insurance. Electromed’s direct to patient approach includes obtaining physician referrals, managing insurance claims, delivering the device to patients’ homes, and providing training on proper use. The firm also offers ongoing clinical support, equipment maintenance, and accessory sales such as replacement garments and batteries to enhance recurring revenue streams.

Electromed holds a niche position in the airway clearance therapy market, competing with established firms such as Baxter (formerly Hill-Rom), Philips (Respironics), and Tactile Medical (AffloVest). Its competitive advantages stem from a direct to patient sales approach, comprehensive reimbursement assistance, ongoing clinical evidence supporting efficacy, and a focus on patient centric product design that improves ease of use and comfort. The company also leverages its intellectual property portfolio, which includes 13 U. S. patents and 46 foreign patents covering its core technology. Market research estimates the U. S. homecare market for high frequency chest wall oscillation was approximately $245 million in calendar year 2024, growing at an 8% compound annual growth rate. Electromed believes bronchiectasis represents the fastest growing diagnostic category, with prevalence increasing about 12% annually, offering a substantial expansion opportunity for its therapy.

The company serves individuals with chronic respiratory conditions such as bronchiectasis, cystic fibrosis, and neuromuscular disorders, as well as patients in post surgical or intensive care units requiring short term airway clearance. Its customers include adult pulmonology clinics, cystic fibrosis centers, neuromuscular clinics, hospitals, and home care providers who rely on Electromed for device delivery, training, and ongoing support. The firm treats both pediatric and adult populations, offering a range of garment sizes to ensure a proper fit for children and grown up patients. By focusing on outpatient and home based care, Electromed aims to reduce hospital readmissions and improve quality of life for those living with long term lung conditions.